Investing in our Long-Term Growth

The Exact Sciences team highlighted the enormous strides we’re making toward our mission of eradicating colon cancer when we recently released preliminary fourth quarter and full-year 2017 results. During the year, approximately 571,000 Cologuard tests were completed, a year-over-year increase of 134 percent. Nearly 11,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2017. The total number of providers who have ordered Cologuard since its launch increased to nearly 102,000.

Exact Logo - No Background (1).png

Since Cologuard was approved by the FDA in 2014, more than 920,000 people have been screened with our easy-to-use colon cancer screening test. As our Chairman and CEO Kevin Conroy highlighted in this recent press release, “An increasing number of people are being screened for colon cancer with our accurate, non-invasive test" 

We expect to report $265-266 million in revenues during 2017, which represents 167 percent growth for the year.  As demand for Cologuard strengthens, we will continue to invest in our team, facilities, and infrastructure to support the company’s long-term growth. We look forward to reporting 2017 financial results and providing revenue and Cologuard test volume guidance for 2018 on our February earnings call. 

Exact Sciences has not completed preparation of its financial statements for the fourth quarter or full year of 2017. The preliminary, unaudited results presented in this news release for the quarter and year ended Dec. 31, 2017, are based on current expectations and are subject to year-end closing adjustments. Actual results may differ. 

Topics: Company